Ann Indian Acad Neurol. 2015 Sep; 18(Suppl 1): S2–S5.
doi: 10.4103/0972-2327.164812
PMCID: PMC4604693
PMID: 26538844
Recommandations francaises pour la prise enc harge du chikungunya
Médecine e tmaladies infectieuses 45(2015)243–263
Kulkarni et al. The Journal of Headache and Pain (2015) 16:67 DOI 10.1186/s10194-015-0549-x
The International Pharmaceutical Federation (FIP) is a global federation of national associations of pharmacists and
pharmaceutical scientists. In order to support these associations in their fight against AMR, FIP has prepared this
briefing document. It is an overview of the different activities ...that community and hospital pharmacists are involved
into prevent AMR and to reverse AMR rates.
more
Public Report
PQMC 0003-003-00 WHO PQMC PR June/2015, version 2.0
Les maladies chroniques non transmissibles (MCNT) constituent un problème de santé publique. La transition épidémiologique coexiste avec les maladies infectieuses. En Afrique subsaharienne, leur ampleur est peu connue et l'OMS recommande aux pays à faible et moyen revenu de réaliser des enquê...tes STEPS portant sur les comportements, des mesures physiques et biochimiques. L'absence de données au niveau national justifie cette étude auprès d'un groupe spécifique. L'objectif de l'étude était de déterminer la prévalence des MCNT et de leurs facteurs de risque chez les militaires Sénégalais.
more
Glob Ment Health (Camb). 2015; 2: e12. Published online 2015 Jul 14. doi: 10.1017/gmh.2015.10
Low and middle income countries (LMICs) are facing an increase of the impact of mental health problems while confronted with limited resources and limited access to mental health care, known as the ‘me...ntal health gap’. One strategy to reduce the mental health gap would be to utilize the internet to provide more widely-distributed and low cost mental health care. We undertook this systematic review to investigate the effectiveness and efficacy of online interventions in LMICs.
more
Gurejeet al. BMC Health Services Research (2015) 15:242
DOI 10.1186/s12913-015-0911-3
Department of Behavioural Medicine, Lagos State University College of Medicine Ikeja, Lagos Nigeria
Global Mental Health (2015), 2, e5, page 1 of 12. doi:10.1017/gmh.2015.8;
Received 29 January 2015; Revised 8 April 2015; Accepted 15 April 2015
EVALUATION REPORT | Esta evaluación es el primer ejercicio mundial de carácter amplio para examinar la respuesta programática del UNICEF en la protección de la infancia en situaciones de emergencia. Su objetivo es fortalecer los programas de protección de la infancia mediante la evaluación del... desempeño en los últimos años y extraer lecciones y recomendaciones que influyan en los programas actuales y futuros. Se espera que los resultados de la evaluación sirvan de base para la puesta en marcha del Plan Estratégico de 2014 a 2017. El diseño de la evaluación incluye estudios de caso de países que analizan los resultados en favor de la infancia con respecto al plan estratégico de mediano plazo (PEMP), los compromisos básicos y preguntas de evaluación seleccionadas. Doce países proporcionaron datos para el análisis, cuatro como estudios de caso con visitas a los países e informes independientes (Colombia, Pakistán, República Democrática del Congo y Sudán del Sur) y otros ocho países con estudios documentales (Afganistán, Estado de Palestina, Filipinas, Haití, Myanmar, Somalia, Sri Lanka y Sudán). Cuatro de los países (Filipinas, Haití, Myanmar y Pakistán) son países afectados por desastres y contextos repentinos, mientras que el resto son sobre todo contextos de conflictos prolongados que incluyen levantamientos violentos repentinos8
more
The aim is to provide early detection of potentially infected persons; to assist in implementing WHO recommendations related to Ebola management; and to prevent the international spread of the disease while allowing PoE authorities to avoid unnecessary restrictions and delays
Ebola Virus Disease Outbreak Response Plan in West Africa July to December 2014. Annex 1
Interim Assessement Report
The EMA review was started by the Agency’s Committee for Medicinal Products for Human Use (CHMP) to support decision-making by health authorities. This first interim report includes information on seven experimental medicines intended for the treatment of people infecte...d with the Ebola virus:
BCX4430 (Biocryst);
Brincidofovir (Chimerix);
Favipiravir (Fujifilm Corporation/Toyama);
TKM-100802 (Tekmira);
AVI-7537 (Sarepta);
ZMapp (Leafbio Inc.);
Anti-Ebola F(ab’)2 (Fab’entech).
The amount of information available for the seven treatments is highly variable. For some compounds there is no data from use in human subjects available. A small number of treatments have been administered to patients in the current Ebola outbreak as compassionate use. Finally, there are also medicines included in this review that have already been studied in humans, albeit for the treatment of other viral diseases.
more